Revolution Medicines (RVMD) Operating Leases (2020 - 2026)

Revolution Medicines' Operating Leases history runs 7 years deep, the most recent figure standing at $140.0 million for Q1 2026.

• In Q1 2026, Operating Leases rose 15.37% year-over-year to $140.0 million; the TTM figure through Mar 2026 stood at $140.0 million (up 15.37% YoY), while the FY2025 annual figure was $142.2 million, up 15.66% from the prior year.
• Operating Leases was $140.0 million for Q1 2026 at Revolution Medicines, down from $142.2 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $142.2 million in Q4 2025 to a low of $57.1 million in Q3 2023.
• Historically, Operating Leases has averaged $89.0 million across 5 years, with a median of $79.1 million in 2024.
• Biggest YoY gain for Operating Leases was 116.88% in 2022; the steepest drop was 4.94% in 2022.
• A 5-year view of Operating Leases shows it stood at $57.4 million in 2022, then surged by 40.3% to $80.6 million in 2023, then surged by 52.62% to $123.0 million in 2024, then grew by 15.66% to $142.2 million in 2025, then decreased by 1.56% to $140.0 million in 2026.
• The last three Operating Leases figures came in at $140.0 million (Q1 2026), $142.2 million (Q4 2025), and $142.1 million (Q3 2025), per Business Quant data.